TY  - CONF

T1  - Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2008.26.15_suppl.8009

PY  - 2008/05/20

AU  - Heymach JV

AU  - Hanrahan EO

AU  - Mann H

AU  - Langmuir P

AU  - Natale RB

AU  - Johnson BE

AU  - Herbst RS

AU  - Ryan AJ

ED  - 

DO  - DOI: 10.1200/jco.2008.26.15_suppl.8009

PB  - American Society of Clinical Oncology (ASCO)

VL  - 26

IS  - 15_suppl

SP  - 8009

EP  - 8009

Y2  - 2024/10/23

ER  -